Gritstone Announces Presentations at Two Investor Conferences in September
September 07 2021 - 4:00PM
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology
company developing the next generation of cancer and infectious
disease immunotherapies, today announced that Gritstone management
will present webcasted company overviews at two upcoming investor
conferences in September.
Conference: H.C. Wainwright 23rd Annual Global
Investment Conference Date and Time: Monday,
September 13, 2021 at 7:00 a.m. ETPresenter:
Andrew Allen, M.D., Ph.D., co-founder, president and chief
executive officer
Conference: Cantor Virtual Global Healthcare
ConferenceDate and Time: Wednesday, September 29,
2021 at 2:40 p.m. ETPresenter: Celia Economides,
executive vice president and chief financial officer
A live webcast of the presentations will be accessible via the
Investors & Media section of the company’s website at
https://ir.gritstonebio.com/investors/events. An archived replay
will be accessible for 30 days following each event.
About Gritstone Gritstone bio, Inc. (Nasdaq:
GRTS), a clinical-stage biotechnology company, is developing the
next generation of immunotherapies against multiple cancer types
and infectious diseases. Gritstone develops its products by
leveraging two key pillars—first, a proprietary machine
learning-based platform, Gritstone EDGE™, which is designed to
predict antigens that are presented on the surface of cells, such
as tumor or virally-infected cells, that can be seen by the immune
system; and, second, the ability to develop and manufacture potent
immunotherapies utilizing these antigens to potentially drive the
patient’s immune system to specifically attack and destroy
disease-causing cells. The company’s lead oncology programs include
an individualized neoantigen-based immunotherapy, GRANITE, and an
“off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which
are being evaluated in clinical studies. Within its infectious
disease pipeline, Gritstone is advancing CORAL, a COVID-19 program
to develop a second-generation vaccine, with support from
departments within the National Institutes of Health (NIH), the
Bill & Melinda Gates Foundation, the Coalition for Epidemic
Preparedness Innovations (CEPI) and through a license agreement
with La Jolla Institute for Immunology. Additionally, the company
has a global collaboration for the development of a therapeutic HIV
vaccine with Gilead Sciences. For more information, please visit
gritstone.com.
Gritstone ContactsMedia:Dan Budwick1AB(973)
271-6085dan@1abmedia.com
Investors:Celia EconomidesChief Financial
Officercelia@gritstone.com
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Apr 2023 to Apr 2024